NCT02811939View on ClinicalTrials.gov

Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone: Sub-Study I

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

April 7, 2016

Primary Completion Date

June 9, 2017

Study Completion Date

June 9, 2017

Conditions
Healthy
Interventions
DRUG

Active Dronabinol

20 mg capsule of Dronabinol will be administered orally

DRUG

Active Pregnenolone

1.79 mg/kg of Pregnenolone will be administered sublingually (under the tongue)

DRUG

Placebo Dronabinol

Control: Placebo pill (no active cannabinoids) administered orally

DRUG

Placebo Pregnenolone

Control: Placebo given sublingually (under the tongue)

Trial Locations (1)

06516

Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine, West Haven

All Listed Sponsors
lead

Yale University

OTHER

NCT02811939 - Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone: Sub-Study I | Biotech Hunter | Biotech Hunter